Details for Patent: 5,981,477
✉ Email this page to a colleague
Title: | Peptide-metal chelate conjugates |
Abstract: | This invention relates to diagnostic and radiodiagnostic agents, including radiolabeled scintigraphic imaging agents, and therapeutic and radiotherapeutic agents. The invention provides such agents and reagents for preparing such agents, and methods for producing and using such reagents. Specifically, the invention provides radiolabeled imaging agents and non-radioactively labeled imaging agents for imaging sites in a mammalian body and reagents for preparing these imaging agents. The invention also provides radiolabeled therapeutic agents, as well as non-radioactively labeled therapeutic agents, and reagents and methods for preparing these agents. The agents and reagents provided comprise a specific binding peptide, covalently linked to a metal ion-complexing moiety. Reagents, methods and kits for making such reagents, methods for labeling such reagents, and methods for using such labeled reagents are provided. |
Inventor(s): | Dean; Richard T. (Bedford, NH) |
Assignee: | Diatide, Inc. (Londonderry, NH) |
Filing Date: | Mar 13, 1998 |
Application Number: | 09/039,116 |
Claims: | 1. A method of treating an animal bearing a somatostatin receptor-expressing tumor, comprising the step of: administering to said animal a therapeutically effective amount of a pharmaceutical composition comprising a somatostatin receptor-binding peptide having a formula: wherein X is a metal ion complexing moiety having formula wherein B is a thiol-containing moiety that is cysteine, homocysteine, isocysteine, or penicillamine; (amino acid).sub.n and (amino acid).sub.m are each independently any primary .alpha.- or .beta.-amino acid that does not comprise a thiol group; Z is --OH or --NH.sub.2 ; n is an integer between 2 and 5; m is an integer between 0 and 5. 2. A method of radioisotope guided surgery, comprising the steps of: a) administering to an animal bearing a somatostatin receptor-expressing tumor an effective amount of a pharmaceutical composition comprising a technetium-99m labeled somatostatin receptor-binding peptide having a formula: wherein X is a metal ion complexing moiety having formula wherein B is a thiol-containing moiety that is cysteine, homocysteine, isocysteine, or penicillamine; (amino acid).sub.n and (amino acid).sub.m are each independently any primary .alpha.- or .beta.-amino acid that does not comprise a thiol group; Z is --OH or --NH.sub.2 ; n is an integer between 2 and 5; m is an integer between 0 and 5; and b) excising tissue containing neoplastic or metastatic cells identified by localization of radioactivity from the pharmaceutical composition. 3. A method of imaging a site within a mammalian body comprising the steps of: a) administering an effective diagnostic amount of a pharmaceutical composition comprising a technetium-99m-labeled somatostatin receptor-binding peptide having a formula: wherein X is a metal ion complexing moiety having formula wherein B is a thiol-containing moiety that is cysteine, homocysteine, isocysteine, or penicillamine; (amino acid).sub.n and (amino acid).sub.m are each independently any primary .alpha.- or .beta.-amino acid that does not comprise a thiol group; Z is --OH or --NH.sub.2 ; n is an integer between 2 and 5; m is an integer between 0 and 5; and b) detecting a radioactive signal from the technetium-99m localized at the site. 4. A method of radioisotope guided surgery, comprising the steps of: a) administering to an animal bearing a somatostatin receptor-expressing tumor an effective amount of a pharmaceutical composition comprising an iodine-123-labeled or iodine-125-labeled somatostatin receptor-binding peptide having a formula: wherein X is a metal ion complexing moiety having formula wherein B is a thiol-containing moiety that is cysteine, homocysteine, isocysteine, or penicillamine; (amino acid).sub.n and (amino acid).sub.m are each independently any primary .alpha.- or .beta.-amino acid that does not comprise a thiol group; Z is --OH or --NH.sub.2 ; n is an integer between 2 and 5; m is an integer between 0 and 5; and b) excising tissue containing neoplastic or metastatic cells identified by localization of radioactivity from the pharmaceutical composition. 5. A method of treating an animal bearing a somatostatin receptor-expressing tumor, comprising the step of: administering to said animal a therapeutically effective amount of a pharmaceutical composition comprising a cytotoxic radioisotope and a somatostatin receptor-binding peptide having a formula: wherein X is a metal ion complexing moiety having formula wherein B is a thiol-containing moiety that is cysteine, homocysteine, isocysteine, or penicillamine; (amino acid).sub.n and (amino acid).sub.m are each independently any primary .alpha.- or .beta.-amino acid that does not comprise a thiol group; Z is --OH or --NH.sub.2 ; n is an integer between 2 and 5; m is an integer between 0 and 5. 6. The method of claim 5, wherein the radioisotope is selected from the group consisting of copper-67, iodine-125, iodine-131, rhenium-186, rhenium-188, tin-117m, and astatine-211. 7. A method of treating an animal bearing a somatostatin receptor-expressing tumor, comprising the step of: administering to said animal a therapeutically effective amount of a pharmaceutical composition comprising a non-radioactive metal ion and a somatostatin receptor-binding peptide having a formula: wherein X is a metal ion complexing moiety having formula wherein B is a thiol-containing moiety that is cysteine, homocysteine, isocysteine, or penicillamine; (amino acid).sub.n and (amino acid).sub.m are each independently any primary .alpha.- or .beta.-amino acid that does not comprise a thiol group; Z is --OH or --NH.sub.2 ; n is an integer between 2 and 5; m is an integer between 0 and 5. 8. The method of claim 7, wherein the metal ion is selected from the group consisting of copper, zinc, and rhenium. |